New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
07:24 EDTADXS, VRTX, RNA, RARE, PLX, NPSP, NLNK, ISIS, GEVA, FOLD, CYTK, CNAT, XOMACanaccord to hold a conference
Orphan Drugs 1:1 Day will be held in New York on February 24.
News For ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA From The Last 14 Days
Check below for free stories on ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
07:40 EDTGEVASynageva management to meet with JPMorgan
Subscribe for More Information
07:38 EDTADXSAdvaxis receives patent in Japan
Advaxis announced that it has received a notice of allowance from the Japan Patent Office for a patent application related to the Advaxis proprietary Lm-LLO cancer immunotherapy platform technology. Once issued, this patent will provide protection in Japan until 2029. The claims under the patent cover composition of matter and methods of use for combining Advaxis's proprietary immunogenic, recombinant tLLO fused to full and partial antigens of particular interest to target cancers such as cervical, ovarian, melanoma, lung, and head and neck. The antigens covered under the claims include HPV-related and prostate cancer antigens, which are expressed in cervical and prostate cancer. Several of these claims are already patented in the United States. This patent along with the other issued patents in Japan, provides stronger protection for current and future uses of Advaxis immunotherapies.
06:35 EDTRNAProsensa upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information
July 23, 2014
11:08 EDTFOLDHigh option volume stocks
Subscribe for More Information
11:06 EDTFOLDSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Amicus Therapeutics' Migalastat for Fabry's disease on an Analyst/Industry conference call to be held on July 23 at 2 pm.
09:08 EDTRAREUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
10:00 EDTRAREOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: American Airlines (AAL) initiated with an Overweight at Atlantic Equities... Apple (AAPL) initiated with a Buy at Citigroup... Basic Energy (BAS) initiated with a Neutral at RW Baird... Brookdale Senior Living (BKD) initiated with a Buy at Goldman... CA Technologies (CA) initiated with a Market Perform at FBR Capital... Dresser-Rand (DRC) initiated with a Neutral at RW Baird... Fortinet (FTNT) initiated with a Neutral at Goldman... Frank's International (FI) initiated with a Hold at Jefferies... Home Bancorp (HBCP) initiated with an Outperform at Fig Partners... Key Energy (KEG) initiated with an Outperform at RW Baird... McDermott (MDR) initiated with a Neutral at Tigress Financial... ORBCOMM (ORBC) initiated with a Neutral at Macquarie... Oil States (OIS) initiated with an Outperform at RW Baird... PBF Energy (PBF) initiated with an Equal Weight at Barclays... Palo Alto (PANW) assumed with a Conviction Buy at Goldman... Proofpoint (PFPT) initiated with a Buy at Goldman... Qlik Technologies (QLIK) initiated with a Market Perform at FBR Capital... Radius Health (RDUS) initiated with a Buy at Canaccord... Seventy Seven Energy (SSE) initiated with a Hold at Jefferies... Superior Energy (SPN) initiated with an Outperform at RW Baird... Tandem Diabetes (TNDM) initiated with an Outperform at William Blair... Trecora Resources (TREC) initiated with a Buy at B. Riley... Ultragenyx (RARE) initiated with an Outperform at RW Baird... United Natural Foods (UNFI) initiated with an Outperform at Oppenheimer... Viper Energy (VNOM) initiated with a Market Perform at Northland... Whiting Petroleum (WLL) initiated with a Buy at Tigress Financial.
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
July 15, 2014
16:08 EDTRAREUltragenyx initiated with an Outperform at RW Baird
Subscribe for More Information
July 14, 2014
10:53 EDTCNATConatus management to meet with SunTrust
Meeting to be held in Baltimore, MD on July 18 hosted by SunTrust.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use